The pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit them to the U.S. Food and Drug Administration mid-year.
from Business News https://ift.tt/AjQuxCw
Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials
April 17, 2024
0
